## Accepted Manuscript

Nasal Septal Perforation Secondary to Systemic Bevacizumab

Mathew Geltzeiler, Toby O. Steele


PII: S0196-0709(16)30611-1

DOI: doi:10.1016/j.amjoto.2017.01.018


Reference: YAJOT 1799

To appear in: American Journal of Otolaryngology–Head and Neck Medicine and Surgery

Received date: 19 December 2016



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



### **ACCEPTED MANUSCRIPT**

## Nasal Septal Perforation Secondary to Systemic Bevacizumab

Mathew Geltzeiler, MD<sup>1,2,</sup> Toby O. Steele, MD<sup>3</sup>

<sup>1</sup>Department of Otolaryngology- Head and Neck Surgery, Oregon Health & Science University, Portland, OR 97239, USA.

<sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA 15213 USA

<sup>3</sup>Department of Otolaryngology – Head and Neck Surgery, University of California Davis, Sacramento, CA 95817 USA

Potential Conflicts of Interest: None

#### Correspondence:

Mathew Geltzeiler, MD, University of Pittsburgh Medical Center Department of Otolaryngology Suite 500 Eye and Ear Institute 200 Lothrop St. Pittsburgh, PA 15213 E-mail: geltzeilermn@upmc.edu

**MeSH Key Words**: avastin, bevacizumab, chemotherapy, nasal septum, perforation, septal perforation, sinonasal pathology, ovarian cancer, hereditary hemorrhagic telangiectasia

Word Count: 1,098

#### Download English Version:

# https://daneshyari.com/en/article/5713737

Download Persian Version:

https://daneshyari.com/article/5713737

<u>Daneshyari.com</u>